Biotech
Denali Therapeutics
Denali Therapeutics raises $217M Series C at $5B valuation
$217M
Total Raised
Series C
Latest Round
2015
Founded
600+
Employees
161 Oyster Point Boulevard, South San Francisco, CA 94080
1 min read
Quick Facts
Valuation
$5B
Latest Round Size
$217M
Latest Round Date
March 2024
Denali Therapeutics: Series C Funding Round
Denali Therapeutics has successfully raised $217M in Series C funding, reaching a valuation of $5B.
Company Overview
Neurodegeneration therapeutics
Funding Details
The Series C round was led by Baillie Gifford, with participation from Redmile Group, Vivo Capital, GV, Fidelity.
Company Information
- Headquarters: 161 Oyster Point Boulevard, South San Francisco, CA 94080
- Founded: 2015
- Employees: 600+
- Category: Biotech
Investment
Denali Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Baillie Gifford: Verified investor in Series C
- Redmile Group: Verified investor in Series C
- Vivo Capital: Verified investor in Series C
- GV: Verified investor in Series C
- Fidelity: Verified investor in Series C
Key Investors
Baillie Gifford
Lead Investor
Verified investor in Series C
Redmile Group
Investor
Verified investor in Series C
Vivo Capital
Investor
Verified investor in Series C
GV
Investor
Verified investor in Series C
Fidelity
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M